Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

  • There is currently no data for SNG

Total Voting Rights

30 Jun 2009 09:56

RNS Number : 7642U
Synairgen plc
30 June 2009
 



30 June 2009

Synairgen plc

("Synairgen" or "the Company")

Total Voting Rights

 

For the purposes of the Financial Services Authority's disclosure and Transparency Rules, the Company's total issued share capital at the date of this notice is 59,745,249. 

The Company's issued share capital consists of 59,745,249 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 59,745,249.

The above figure of 59,745,249 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For more information please contact:

 

Synairgen plc  Tel: + 44 (0) 2380 512 800

Richard Marsden, Managing Director

John Ward, Finance Director

Matrix Corporate Capital  Tel: + 44 (0) 20 3206 7000

Alastair Stratton

Anu Tayal

Threadneedle Communications  Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRCKKKPFBKKAAN
Date   Source Headline
11th May 20205:41 pmRNSHolding(s) in Company
6th May 20205:07 pmRNSHolding(s) in Company
5th May 202011:05 amRNSSecond Price Monitoring Extn
5th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 202012:09 pmRNSExtension of clinical study in COVID-19 patients
28th Apr 20205:16 pmRNSHolding(s) in Company
24th Apr 20205:10 pmRNSHolding(s) in Company
16th Apr 20205:35 pmRNSHolding(s) in Company
15th Apr 20201:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202012:00 pmRNSResult of General Meeting
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20204:41 pmRNSSecond Price Monitoring Extn
8th Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20204:56 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSCommencement of dosing in COVID-19 trial
30th Mar 20204:42 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 202011:05 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
30th Mar 20209:05 amRNSSecond Price Monitoring Extn
30th Mar 20209:00 amRNSPrice Monitoring Extension
27th Mar 20203:21 pmRNSHolding(s) in Company
26th Mar 20209:00 amRNSResult of Fundraising
25th Mar 20201:45 pmRNSProposed Fundraising
25th Mar 202011:05 amRNSSecond Price Monitoring Extn
25th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20208:24 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSSecond Price Monitoring Extn
23rd Mar 202011:00 amRNSPrice Monitoring Extension
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
20th Mar 20202:00 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 20209:05 amRNSSecond Price Monitoring Extn
19th Mar 20209:00 amRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSSynairgen to start trial of SNG001 in COVID-19
10th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Oct 20193:53 pmRNSHoldings in Company
16th Oct 20197:30 amRNSHolding(s) in Company
30th Sep 20197:00 amRNSHalf-year Report
27th Sep 20197:00 amRNSPhase II Biomarker Data for SNG001 to be presented
24th Jul 20197:00 amRNSPhase II Clinical Trial Update
8th Jul 20195:48 pmRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.